- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.10. | Biophytis GAAP EPS of -€9.48 | 4 | Seeking Alpha | ||
| 30.09. | Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities | 367 | ACCESSWIRE | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on developing... ► Artikel lesen | |
| 30.09. | BIOPHYTIS: Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities | 3 | Euronext | ||
| BIOPHYTIS SA ADR Aktie jetzt für 0€ handeln | |||||
| 30.09. | Biophytis SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.07. | Biophytis SA - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 22.07. | Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia | 407 | ACCESSWIRE | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| 11.07. | Biophytis SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.07. | Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity | 296 | ACCESSWIRE | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 01.07. | Biophytis SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.07. | Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris | 358 | ACCESSWIRE | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 28.06. | NSE - Biophytis SA - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 26.06. | Delisting of Securities of PHP Ventures Acquisition Corp.; Green Giant Inc.; RMG Acquisition Corp. III; Biophytis SA; OMNIQ Corp.; AIB Acquisition Corporation; Goal Acquisitions Corp.; Applied UV, Inc.; Cue Health Inc. and others | 252 | GlobeNewswire (Europe) | NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, rights, warrants, and units of PHP Ventures Acquisition Corp. PHP Ventures Acquisition... ► Artikel lesen | |
| 20.06. | Biophytis SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 20.06. | Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million | 329 | ACCESSWIRE | Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the productAgreement covers commercialization of BIO101... ► Artikel lesen | |
| 20.06. | Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities | 416 | ACCESSWIRE | Important note: Biophytis has set up financing in the form of Bonds redeemable in cash and in new and existing shares (ORNANE) with the company Atlas, which, after having received the shares resulting... ► Artikel lesen | |
| 12.06. | Biophytis Announces the Successful Industrial Transfer of BIO101 Production by its Service Provider Seqens | 319 | ACCESSWIRE | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 10.06. | Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity | 285 | ACCESSWIRE | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 07.06. | Biophytis SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 07.06. | Biophytis: Combined General Meeting of June 24, 2024 | 188 | ACCESSWIRE | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 14.05. | Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity | 598 | ACCESSWIRE | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,030 | -0,20 % | Deutsche Telekom, GFT Technologies, TeamViewer, TUI, RWE, Valneva - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIOFRONTERA | 2,600 | -3,70 % | PTA-PVR: Biofrontera AG: Mitteilung über Mitteilungspflichten für Inhaber wesentlicher Beteiligungen gemäß § 43 WpHG | DJ PTA-PVR: Biofrontera AG: Mitteilung über Mitteilungspflichten für Inhaber wesentlicher Beteiligungen gemäß § 43 WpHG
Mitteilungspflichten für Inhaber wesentlicher Beteiligungen gemäß § 43 WpHG... ► Artikel lesen | |
| AAP IMPLANTATE | 2,080 | +1,96 % | EQS-Adhoc: aap Implantate AG: Anhebung der EBITDA Guidance | EQS-Ad-hoc: aap Implantate AG / Schlagwort(e): Prognoseänderung
aap Implantate AG: Anhebung der EBITDA Guidance
18.11.2024 / 20:12 CET/CEST
Veröffentlichung einer Insiderinformation nach... ► Artikel lesen | |
| MAINZ BIOMED | 0,194 | -2,70 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung zur Entwicklung von Darmkrebsfrüherkennungstest der nächsten Generation für den globalen Markt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Kooperation
Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung zur Entwicklung von Darmkrebsfrüherkennungstest... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 1,790 | -0,58 % | Sangamo stock climbs 12% post-market on FDA update for ST-503 | ||
| INTELLIA THERAPEUTICS | 14,335 | +4,41 % | Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung - die Hintergründe | Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr. als Gesundheitsminister für die künftige Regierung nominieren zu wollen,... ► Artikel lesen | |
| VIKING THERAPEUTICS | 49,670 | -1,64 % | PTA-News: Small- & MicroCap Investment: Die +440 %-Chance: NurExone mit dreistelligem Gewinn wie Vera Therapeutics oder Viking Therapeutics? | DJ PTA-News: Small- & MicroCap Investment: Die +440 %-Chance: NurExone mit dreistelligem Gewinn wie Vera Therapeutics oder Viking Therapeutics?
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| SCORPIUS | 0,665 | 0,00 % | Scorpius Holdings Introduces Scorpius Ventures | ||
| EDITAS MEDICINE | 2,415 | +3,29 % | Editas Medicine, Inc.: Editas Medicine Announces Third Quarter 2024 Results and Business Updates | Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 109,65 | -0,05 % | Analyst Expectations For Sarepta Therapeutics' Future | ||
| REDHILL BIOPHARMA | 6,850 | -0,58 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
| IBIO | 2,640 | 0,00 % | iBio, Inc. - 8-K, Current Report | ||
| BLUEBIRD BIO | 0,389 | +16,53 % | bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September... ► Artikel lesen | |
| GERON | 3,843 | -1,46 % | Geron Corporation Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Geron Corporation (GERN) reported Loss for third quarter that decreased from last year and beat the Street estimates.The company's bottom line totaled -$26.45 million... ► Artikel lesen |
Das Unternehmen BIOPHYTIS SA ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,224 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOPHYTIS SA ADR finden Sie auf Wallstreet Online.
